Organization and Principal Activities (Details Narrative) - USD ($) |
Aug. 25, 2020 |
Sep. 30, 2020 |
Dec. 31, 2019 |
|---|---|---|---|
| Liabilities | $ 872,687 | $ 910 | |
| Common shares | 500,000 | 500,000 | |
| Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member] | |||
| Percentage of acquisition ownership interest | 100.00% | ||
| Percentage of common stock outstanding | 75.00% | ||
| Liabilities | $ 3,429,516 | $ 3,429,516 | |
| Common shares | 7,907,351 | 7,907,351 |
| X | ||||||||||
- Definition Percentage of common stock outstanding. No definition available.
|
| X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|